In the article, the researchers aimed to identify prognostic biomarkers of CMV-related fetal brain injury and identified two amniotic fluid proteins that could be employed in the clinical setting to profoundly improve the prognostic assessment of CMV-infected fetuses.
Figure 4. Amniotic fluid chemerin (A) and Gal-3BP (B) levels in fetuses with severe cCMV (SCC), sensorineural hearing loss (SNHL), asymptomatic cCMV (ACC), and in uninfected fetuses
